NCT07169500招募中1 期
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年3月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Assessment and comparison of MRD negativity rate 3 months after BCMA-CART±ASCT
研究概览
简要总结
Evaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients
详细描述
This study is a single-center, open-label, prospective investigator-initiated clinical study. Patients are assigned to treatment groups in a non-randomized manner based on their condition and disease status, and are divided into transplant and non-transplant groups according to whether ASCT is combined. The study analyzes and compares the safety and efficacy of BCMA-CART ± ASCT treatment in young MM patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Young female, 18-55 years old;
- •Subjects voluntarily participate in the study and sign the informed consent form (ICF) themselves or through their legal guardian;
- •Confirmed diagnosis of multiple myeloma through flow cytometry or immunohistochemistry;
- •Subjects must have adequate organ function and meet all of the following test results:
- •Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN)
- •Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
- •Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 40 ml/min
- •Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) < 1.5 × ULN, international normalized ratio (INR) < 1.5 × ULN
- •Hemoglobin (Hb) ≥ 60 g/L
- •Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L (no granulocyte colony-stimulating factor [G-CSF] or other growth factors received within 7 days prior to screening laboratory tests)
- •Absolute lymphocyte count (ALC) ≥ 0.5 × 10^9/L
- •Platelets (PLT) ≥ 50 × 10^9/L (no platelet transfusion received within 7 days prior to screening laboratory tests)
- •Left ventricular ejection fraction (LVEF) ≥ 45%
- •Blood oxygen saturation (SpO2) ≥ 92%
- •ECOG score of 0-1, see Appendix 5 for ECOG scoring;
- •Expected survival ≥ 3 months;
- •Female participants of childbearing potential must have a negative pregnancy test and not be breastfeeding; female or male participants of childbearing potential must use effective contraceptive methods or devices for 24 months after cell infusion.
排除标准
- •History of allergy to any component of the cellular product;
- •Severe heart disease, including but not limited to:
- •Myocardial infarction, coronary angioplasty, or stent implantation within 6 months prior to signing the ICF
- •Unstable angina
- •Severe arrhythmia
- •History of severe non-ischemic cardiomyopathy
- •Congestive heart failure (New York Heart Association [NYHA] class III or IV), NYHA scores are in Appendix 2
- •Stroke or seizure within 6 months prior to signing the ICF;
- •Autoimmune diseases, immunodeficiency, or other conditions requiring immunosuppressive therapy;
- •Malignant tumors other than multiple myeloma within 3 years prior to signing the ICF, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and other in situ cancers at other sites one year after radical surgery, provided there is no ongoing treatment and no signs of recurrence during the screening period;
- •Presence of uncontrolled active infection;
- •Unstable systemic diseases as judged by the investigator, including but not limited to severe liver, kidney, or metabolic diseases requiring medication.
- •Within one week before lymphocyte collection, the storage device falls under any of the following conditions:
- •Peripheral blood hepatitis B virus (HBV) DNA test value is above the detection limit
- •Hepatitis C virus (HCV) antibody positive and peripheral HCV-RNA positive
- •Human immunodeficiency virus (HIV) antibody positive
- •Syphilis antigen or antibody positive
- •CMV-DNA positive
- •Within one week before lymphocyte collection, use of more than 5 mg/day of prednisone (or an equivalent dose of other corticosteroids);
- •Prior use of any CAR-T cell products or other genetically modified T cell therapies;
- •Prior BCMA-targeted therapy;
- •Vaccination with a live vaccine within 4 weeks before signing the ICF;
- •History of alcoholism, drug abuse, or psychiatric disorders; Other conditions that the investigator deems unsuitable for participation in this study.
研究组 & 干预措施
BCMA-CART
Experimental
All study participants are non-randomly assigned based on their disease status before the start of treatment. Those suitable for transplantation enter the transplantation (ASCT CART) treatment group, while those not suitable for transplantation enter the non-transplant treatment group.
Participants in the transplant group will undergo ASCT at an appropriate time before receiving BCMA-CART treatment. Participants in the non-transplant group do not need to undergo ASCT and can proceed directly to BCMA-CART treatment at an appropriate time.
干预措施: CAR-T (Biological)
结局指标
主要结局
Assessment and comparison of MRD negativity rate 3 months after BCMA-CART±ASCT
时间窗: 3 month
MRD by flow cytometry
次要结局
- Progression-free Survival (PFS)(2 years after CAR-T infusion)
- Minimal Residual Disease (MRD) negetive rate(at day28, M2, M3, M6, M9, M12, M15, M18, M24 after CAR-T infusion)
- Overall response rate (ORR) evaluated by the investigators(2 years after CAR-T infusion)
- Duration of Response (DOR)(2 years after CAR-T infusion)
- Time to Response (TTR)(2 years after CAR-T infusion)
- Overall Survival (OS)(2 years after CAR-T infusion)
- PK:Cmax,Tmax,AUC(0-28days),Tlast(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MMPlasma Cell LeukemiaNCT07109323Institute of Hematology & Blood Diseases Hospital, China50
招募中
2 期
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCLNCT07106723Institute of Hematology & Blood Diseases Hospital, China50
招募中
1 期
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaMultiple MyelomaNCT05740891Zhejiang University50
招募中
早期 1 期
Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant LymphomaLymphomaNCT05239676Zhejiang University50
招募中
2 期
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia ALLNCT06608342Institute of Hematology & Blood Diseases Hospital, China20